A promising outlook for diabetic kidney disease

Mark Cooper, Annabelle M. Warren

Research output: Contribution to journalArticleOtherpeer-review

6 Citations (Scopus)


In 2018, consolidating evidence for renoprotective benefits was seen with respect to sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide 1 agonists, which are currently being incorporated into clinical practice. The focus now turns to novel therapeutic targets to optimize renoprotection as diabetic kidney disease grows to epidemic proportions worldwide.

Original languageEnglish
Pages (from-to)68-70
Number of pages3
JournalNature Reviews Nephrology
Issue number2
Publication statusPublished - 1 Feb 2019

Cite this